Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2009

GE Healthcare to Provide Cytori’s Adipose-Derived Stem Cell Technology in North America

  • GE Healthcare agreed to commercialize Cytori Therapeutics’ StemSource® technology in the North American stem cell banking and research markets. The partnership will extend for 18 months starting in the second quarter of 2009.

    StemSource includes automated equipment to process stem and regenerative cells found in adipose tissue, cryopreserve them, or use them directly for research purposes.

    In January 2009, Cytori and GE Healthcare formed a separate agreement to commercialize Cytori’s products in 10 European countries. This includes selling the Celution® 800/CRS System in the European cosmetic and reconstructive surgery market as well as selling

    StemSource products in the European cell banking and research markets.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »